Superworth

BioStem Technologies BSEM

Biotechnology, Healthcare
$1.16
+3.57%
Market cap
$20.7M
PE
n/m
one or more of the four quarters through 2026-06-30 missing
Forward PE
n/m
not a meaningful number
Price to sales
n/m
one or more of the four quarters through 2026-06-30 missing
EV/EBIT
n/m
not a meaningful number
Revenue, 12 months
n/m
one or more of the four quarters through 2026-06-30 missing
Net margin
n/m
one or more of the four quarters through 2026-06-30 missing
Free cash flow yield
n/m
not a meaningful number

Charts

Financials

Income statement for BSEM, by quarter
Income statementQ1 FY25Q2 FY25Q1 FY26Q2 FY26
$16M$11M$6.1M$7.9M
Cost of revenue$853.4K$685.2K$2.4M$3.1M
Gross profit$15.1M$10.3M$3.8M$4.8M
R&D$1.7M$2M$1.1M$733.6K
SG&A$8.1M$8.1M$11M$11.8M
$5.2M$112.8K−$8.9M−$8.4M
Pre-tax income$5.3M$178K−$8.8M−$9M
$1.4M$167.3K$0$0
Net income$3.9M$10.6K−$8.8M−$9M
$0.17$0.00−$0.52−$0.52
23.6M23.4M16.8M17.3M

Revenue: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Cost of revenue: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Gross profit: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

R&D: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

SG&A: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Operating income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Pre-tax income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Income tax: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Net income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

EPS, diluted: Q1 FY25 and Q1 FY26: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY25 and Q1 FY26: share-days: the 6-month average less the second quarter's.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Healthcare nearest BioStem Technologies' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
BSEMBioStem Technologies$20.7Mn/mn/an/mn/mn/m
NEPHNephros$35.2M20.3×28.3×1.7×+24%8.4%
ATNMActinium Pharmaceuticals$45M4.0×3.3×n/mn/mn/m
APTAlpha Pro Tech$56.3M13.5×14.8×0.9×+6%6.8%
SPROSpero Therapeutics$60.6M9.5×9.5×1.3×−3%15.7%
LFVNLifevantage$73.5M14.7×19.4×0.4×−20%2.8%
ICCCImmucell$95.9M132×44.1×3.1×+8%2.6%
KEQUKewaunee Scientific$96.7M12.1×13.6×0.3×+5%3.0%
PDEXPro DEX$184.5M15.9×16.5×2.3×+13%15.1%
PLXProtalix BioTherapeutics$206.3M11.1×33.6×2.6×+30%23.5%
Peer median$73.5M13.5×16.5×1.5×+7%7.6%

More on BioStem Technologies

Its groups

About

Industry
Biotechnology
Sector
Healthcare

Valuation data, not investment advice. Prices as of .